MTRAC update glitazone advice

April 11, 2008 at 10:03 am | In Prescribing Extra - Drugs | Print Print | No Comments

The Midlands Therapeutics Review and Advisory Committee (MTRAC) has issued updated advice for pioglitazone (Actos®) and rosiglitazone (Avandia®).

The pioglitazone review places this drug as having weaker evidence and having a lower place in therapy. It is suitable for restricted prescribing in primary care because of conflicting evidence in the long-term clinical effects of this drug on cardiovascular outcomes.

The rosiglitazone review recommends that this drug should not be prescribed in primary care because of “inadequate evidence of safety and/or efficacy“.

Action: Current recommendations still stand. Metformin continues to be the first choice oral hypoglycaemic with a sulphonylurea added in as second line. This is based upon a proven record of efficacy and safety.

Copyright ©2008 Prescribing Advice for GPs

No Comments yet »

RSS feed for comments on this post. TrackBack URI

Leave a comment

XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS Feed for New Entries.
Akismet has protected Prescribing Advice for GPs from 5,569 spam comments.